Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Matteo Giovanni Carrabba, MD, Monica Casucci, PhD, Michael Hudecek, MD, Concetta Quintarelli, PhD, Javier Briones, MD, Roman Hajek, MD PhD, Jorge Sierra, MD, Franco Locatelli, Hermann Einsele, MD PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Catia Traversari, PhD

Blood (2018) 132 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2018-99-117974

Published: 2018

Journal Articles

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Blood (2018) 132 (Supplement 1): 559.

https://doi.org/10.1182/blood-2018-99-118494

Published: 2018

Journal Articles

Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis

Aleksandr Lazaryan, MD PhD MPH, Michelle Dolan, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Veronika Bachanova, MD PhD, Marcos De Lima, MD, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2017) 130 (Supplement 1): 1439.

https://doi.org/10.1182/blood.V130.Suppl_1.1439.1439

Published: 2017

Journal Articles

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Haneen Shalabi, DO, Nirali N Shah, MD, Terry J. Fry, MD, Bonnie Yates, RN, Cynthia Delbrook, RN, Constance Yuan, Maryalice Stetler-Stevenson, Sneha Ramakrishna, MD

Blood (2017) 130 (Supplement 1): 3889.

https://doi.org/10.1182/blood.V130.Suppl_1.3889.3889

Published: 2017

Journal Articles

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Jeffrey W. Taub, Jason N. Berman, Johann K. Hitzler, April D. Sorrell, Norman J. Lacayo, Kelley Mast, David Head, Susana Raimondi, Betsy Hirsch, Yubin Ge, Robert B. Gerbing, Yi-Cheng Wang, Todd A. Alonzo, Dario Campana, Elaine Coustan-Smith, Prasad Mathew, Alan S. Gamis

Blood (2017) 129 (25): 3304–3313.

https://doi.org/10.1182/blood-2017-01-764324

Published: 2017

Includes: Supplemental data

Journal Articles

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

Virginie Lavoipierre, Samia Harbi, MD, Luca Castagna, MD, Angela Granata, MD, Sabine Fürst, MD, Catherine Faucher, MD, Faezeh Legrand, Stefania Bramanti, MD, Christian Chabannon, MD PhD, Norbert Vey, MD PhD, Jérome Rey, Reda Bouabdallah, MD, Jean Marc Schiano De Colella, Djamel Mokart, Pierre-Jean Weiller, Prof., Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2016) 128 (22): 4618.

https://doi.org/10.1182/blood.V128.22.4618.4618

Published: 2016

Journal Articles

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 4181.

https://doi.org/10.1182/blood.V126.23.4181.4181

Published: 2015

Journal Articles

Risk organ + LCH gets the one-two punch?

Kimo C. Stine

Blood (2015) 126 (12): 1399–1400.

https://doi.org/10.1182/blood-2015-08-661496

Published: 2015

Journal Articles

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis A. Gimotty, PhD, Gerald Wertheim, MDPhD, Catherine Smith, Alison R. Sehgal, MD, Selina M. Luger, MD, Stephen R. Master, MDPhD, Alison W. Loren, MD, Martin P. Carroll, MD

Blood (2014) 124 (21): 2345.

https://doi.org/10.1182/blood.V124.21.2345.2345

Published: 2014

Journal Articles

CD271+ Mesenchymal Stromal Cell Density Is High In Poor-Risk MDS and Independently Predicts Overall Survival

Ryan C. Johnson, MD, Peter L. Greenberg, MD, Dita Gratzinger, MD, PhD

Blood (2013) 122 (21): 1560.

https://doi.org/10.1182/blood.V122.21.1560.1560

Published: 2013

Journal Articles

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Daniel Turner, BS, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Raphael C Bosse, BS, Dai Chaplin, PhD, Jack W. Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, Maxim Norkin, MD, PhD, John R Wingard, MD, Christopher R Cogle, MD

Blood (2013) 122 (21): 1463.

https://doi.org/10.1182/blood.V122.21.1463.1463

Published: 2013

Journal Articles

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Christopher R Cogle, MD, Andres Gonzalez, BS, Leslie Pettiford, RN, Amy Meacham, MS, Elizabeth Wise, BS, Maxim Norkin, MD, PhD, David Chaplin, PhD, Jai Balkissoon, MD, Jack W Hsu, MD, Randy A Brown, MD, John W Hiemenz, MD, John R Wingard, MD

Blood (2012) 120 (21): 4335.

https://doi.org/10.1182/blood.V120.21.4335.4335

Published: 2012

Journal Articles

Host Pharmacogenetic Factors Significantly Contribute to Refinement of Prognosis in Children with Acute Lymphoblastic Leukemia (ALL): Result From the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Yi Lu, Ph.D., Shirley Kow Yin Kham, B.Sc., Arrifin Hany, M.D., Ah Moy Tan, M.D., Thuan Chong Quah, M.D., Allen Eng Juh Yeoh, M.D.

Blood (2011) 118 (21): 567.

https://doi.org/10.1182/blood.V118.21.567.567

Published: 2011

Journal Articles

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Todd A. Alonzo, PhD, Phoenix A. Ho, MD, Robert B. Gerbing, MA, Alan S. Gamis, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd Cooper, DO, Janet Franklin, MD, MPH, Laura Pardo, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2010) 116 (21): 761.

https://doi.org/10.1182/blood.V116.21.761.761

Published: 2010

Journal Articles

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

Tait Shanafelt, MD, Han Tun, MD, Curtis Hanson, Clive S. Zent, MD, Jose Leis, Timothy Call, MD, Betsy LaPlant, Deborah Bowen, Kristina Laumann, Diane F. Jelinek, PhD, Neil E. Kay

Blood (2010) 116 (21): 1379.

https://doi.org/10.1182/blood.V116.21.1379.1379

Published: 2010

Journal Articles

T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)

Jonathan Downie, BS, Phillip Barnette, MD, Vladimir Rodic, BS, J. Kimble Frazer, MD, PhD, Nikolaus Trede, MD, PhD, Meenakshi Devidas, PhD, Charles Mullighan, MBBS, MD, FRACP, FRCPA, MSc, Stephen Hunger, MD, Rodney R. Miles, MD, PhD, Joshua D. Schiffman, MD

Blood (2010) 116 (21): 275.

https://doi.org/10.1182/blood.V116.21.275.275

Published: 2010

Journal Articles

Molecular Indicators of High-Risk Disease.

John D. Shaughnessy, Jr., PhD, Bart Barlogie

Blood (2008) 112 (11): sci-6.

https://doi.org/10.1182/blood.V112.11.sci-6.sci-6

Published: 2008

Journal Articles

An Analysis of Toxicities and Time to Engraftment Associated with Three Distinct Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving Autologous Hematopoetic Stem Cell Transplantation.

Ila Maewal, PharmD, Andy J Kurtzweil, PharmD, Jamie F Shapiro, PharmD, Michael D Westmoreland, PharmD, Roland L Bassett, Sergio Giralt, MD

Blood (2008) 112 (11): 2161.

https://doi.org/10.1182/blood.V112.11.2161.2161

Published: 2008

Journal Articles

Functional Engraftment of Retrovirally Transduced and Pre-Selected Hematopoietic Cells into Partially Ablated Recipient Fabry Mice.

Jeffrey A. Medin, PhD, Sheng-Ben Liang, MD, PhD, Armando Poeppl, Makoto Yoshimitsu, MD, Jagdeep S. Walia, MBBS, Jianhui Cai, MD, PhD, Vanessa I. Rasaiah, Daniel H. Fowler, MD

Blood (2005) 106 (11): 3023.

https://doi.org/10.1182/blood.V106.11.3023.3023

Published: 2005

NARROW

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis

Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients

Risk organ + LCH gets the one-two punch?

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

CD271+ Mesenchymal Stromal Cell Density Is High In Poor-Risk MDS and Independently Predicts Overall Survival

A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Host Pharmacogenetic Factors Significantly Contribute to Refinement of Prognosis in Children with Acute Lymphoblastic Leukemia (ALL): Result From the Malaysia-Singapore (Ma-Spore) ALL 2003 Study

Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-Based Therapy Allocation In Childhood AML- a Report From the Children's Oncology Group

Lendalidomide Consolidation After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL

T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL)

Molecular Indicators of High-Risk Disease.

An Analysis of Toxicities and Time to Engraftment Associated with Three Distinct Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving Autologous Hematopoetic Stem Cell Transplantation.

Functional Engraftment of Retrovirally Transduced and Pre-Selected Hematopoietic Cells into Partially Ablated Recipient Fabry Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only